Clinical Trial Update: Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome [Phase 4]

View source ↗

Summary

Phase 4 trial update assessing low-dose PCSK9 inhibitor with statins and its effect on serum lipids in Chinese patients with acute coronary syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• PCSK9 inhibitor (low-dose)
• Statins

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Acute Coronary Syndrome | Phase 4 | Status: UNKNOWN